Novel sorafenib analogues induce apoptosis through SHP-1 dependent STAT3 inactivation in human breast cancer cells

Introduction: Signal transducers and activators of transcription 3 (STAT3) signaling is constitutively activated in various cancers including breast Cancer and has emerged as a novel potential anti-cancer target. STAT3 has been demonstrated to be a target of sorafenib, and a protein tyrosine Phosphatase Src homology 2-domain containing tyrosine Phosphatase 1 (SHP-1) has been demonstrated to downregulate p-STAT3 via its Phosphatase activity. Here, we tested the efficacy of two sorafenib analogues, SC-1 and SC-43, in breast Cancer cells and examined the drug mechanism.

Methods: Breast Cancer cell lines were used for in vitro studies. Cell viability was examined by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Apoptosis was examined by flow cytometry and western blot. Signal transduction pathways in cells were assessed by western blot. In vivo efficacy of sorafenib, SC-1 and SC-43 was tested in xenografted nude mice.

Results: SC-1 and SC-43 induced more potent Apoptosis than sorafenib, in association with downregulation of p-STAT3 and its downstream proteins cyclin D1 and Survivin in a dose-dependent manner in breast Cancer cell lines (HCC-1937, MDA-MB-468, MDA-MB-231, MDA-MB-453, SK-BR3, MCF-7). Overexpression of STAT3 in MDA-MB-468 cells protected the cells from Apoptosis induced by sorafenib, SC-1 and SC-43. Moreover, SC-1 and SC-43 upregulated SHP-1 activity to a greater extent than sorafenib as measured by in vitro Phosphatase assays. Knockdown of SHP-1 by siRNA reduced Apoptosis induced by SC-1 and SC-43. Importantly, SC-1 and SC-43 showed more efficacious antitumor activity and p-STAT3 downregulation than sorafenib in MDA-MB-468 xenograft tumors.

Conclusions: Novel sorafenib analogues SC-1 and SC-43 induce Apoptosis through SHP-1 dependent STAT3 inactivation and demonstrate greater potency than sorafenib in human breast Cancer cells.